RU96115196A - COMPOSITION FOR CONTRACEPTION - Google Patents

COMPOSITION FOR CONTRACEPTION

Info

Publication number
RU96115196A
RU96115196A RU96115196/14A RU96115196A RU96115196A RU 96115196 A RU96115196 A RU 96115196A RU 96115196/14 A RU96115196/14 A RU 96115196/14A RU 96115196 A RU96115196 A RU 96115196A RU 96115196 A RU96115196 A RU 96115196A
Authority
RU
Russia
Prior art keywords
estrogen
estradiol
gestodene
levonorgestrel
drospirenone
Prior art date
Application number
RU96115196/14A
Other languages
Russian (ru)
Other versions
RU2169567C2 (en
Inventor
Шпона Юрген
Дюстерберг Бернд
Людике Франк
Файхтингер Вильфрид
Эльстейн Макс
Original Assignee
Шеринг Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE4344462A external-priority patent/DE4344462C2/en
Application filed by Шеринг Аг filed Critical Шеринг Аг
Publication of RU96115196A publication Critical patent/RU96115196A/en
Application granted granted Critical
Publication of RU2169567C2 publication Critical patent/RU2169567C2/en

Links

Claims (16)

1. Применение состава, включающего эстроген, выбираемый из 2,0 - 6,0 мг 17 β -эстрадиола и 0,015 - 0,020 мг этинилэстрадиола, и гестаген, выбираемый из 0,05 - 0,075 мг гестодена, 0,075 - 0,125 мг левоноргестрела, 0,06 - 0,15 мг дезогестрела, 0,06 - 0,15 мг 3-кето-дезогестрела, 0,1 - 0,3 мг дроспиренона, 0,1 - 0,2 мг ципротеронацетата, 0,2 - 0,3 мг норгесимата и > 0,35 - 0,75 мг норэтистерона, для получения дозировочной формы с целью контрацепции для женщины в возрасте, в котором она способна производить потомство, которая еще не достигла предменопаузы, путем введения дозировочной формы в течение 23-х или 24-х дней, начиная с первого дня менструального цикла, с последующими 5 или 4 днями без приема пилюль или с приемом пилюль, не содержащих лекарственного средства, в течение в целом 28 дней в цикле введения.1. The use of the composition, including estrogen, selected from 2.0 - 6.0 mg of 17 β-estradiol and 0.015 - 0.020 mg of ethinyl estradiol, and gestagen, selected from 0.05 - 0.075 mg of gestodene, 0.075 - 0.125 mg of levonorgestrel, 0, 06 - 0.15 mg of desogestrel, 0.06 - 0.15 mg of 3-keto-desogestrel, 0.1 - 0.3 mg of drospirenone, 0.1 - 0.2 mg of cyproterone acetate, 0.2 - 0.3 mg norgesimate and> 0.35 - 0.75 mg of norethisterone, to obtain a dosage form for contraception for a woman at the age at which she is able to produce offspring that have not yet reached premenopausal, by administering the dosage form during 23 or 24 days from the first day of the menstrual cycle, followed by 5 or 4 pill-free days or with taking the pills containing no drug for a total of 28 days in the administration cycle. 2. Применение по п. 1, в котором эстрогеном является этинилэстрадиол. 2. The use according to claim 1, wherein the estrogen is ethinyl estradiol. 3. Применение по п. 1, в котором эстрогеном является 17 β -эстрадиол. 3. The use according to claim 1, wherein the estrogen is 17β-estradiol. 4. Применение по пп. 1, 2 или 3, в котором гестагеном является гестоден. 4. The use of paragraphs. 1, 2 or 3, in which the gestogen is gestodene. 5. Применение по пп. 1, 2 или 3, в котором гестагеном является левоноргестрел. 5. The use of paragraphs. 1, 2 or 3, in which the progestogen is levonorgestrel. 6. Применение по пп. 1, 2 или 3, в котором гестагеном является ципротеронацетат или дроспиренон. 6. The use of paragraphs. 1, 2 or 3, in which the progestogen is cyproterone acetate or drospirenone. 7. Применение по п. 1, в котором дозировочная форма включает эстроген, выбираемый из > 2,0 - 6,0 мг 17 β -эстродиола и 0,020 мг этинилэстрадиола, и гестаген, выбираемый из > 0,06 - 0,075 мг гестодена, > 0,100 - 0,125 мг левоноргестрела, > 0,10 - 0,15 мг дезогестрела, > 0,10 - 0,15 мг 3-кето-дезогестрела, 0,25 - 0,30 мг дроспиренона, 0,1 - 0,2 мг ципротеронацетата, 0,2 - 0,3 мг норгестимата и 0,50 - 0,75 мг норэтистерона. 7. The use according to claim 1, wherein the dosage form comprises an estrogen selected from> 2.0 to 6.0 mg of 17 β-estrodiol and 0.020 mg of ethinyl estradiol, and a gestogen selected from> 0.06 to 0.075 mg of gestodene,> 0,100 - 0,125 mg of levonorgestrel,> 0.10 - 0.15 mg of desogestrel,> 0.10 - 0.15 mg of 3-keto-desogestrel, 0.25 - 0.30 mg of drospirenone, 0.1 - 0.2 mg cyproterone acetate, 0.2-0.3 mg of norgestimate and 0.50-0.75 mg of norethisterone. 8. Применение по п. 1, в котором эстроген находится в дозе 20 мкг этинилэстрадиола или эквивалентной дозе 17 β -эстрадиола и гестаген находится в дозе 75 мкг гестедена или эквивалентной дозе левоноргестрела, ципротеронацетата или драспиренона. 8. The use according to claim 1, wherein the estrogen is in a dose of 20 μg of ethinyl estradiol or an equivalent dose of 17 β-estradiol and the gestagen is in a dose of 75 μg gesteden or an equivalent dose of levonorgestrel, cyproterone acetate or draspirenone. 9. Однофазный комбинированный продукт для пероральной контрацепции, отличающийся тем, что он включает:
а) 23 или 24 дозировочных единицы, смотря по обстоятельствам, содержащих эстроген, выбираемый из > 2,0 - 6,0 мг 17 β -эстрадиола и 0,020 мг этинилэстрадиола; и гестаген, выбираемый из > 0,06 - 0,75 мг гестодена, > 0,100 - 0,125 мг левоноргестрела, > 0,10 - 0,15 мг дезогестрела, > 0,10 - 0,15 мг 3-кето-дезогестрела, 0,25 - 0,30 мг дроспиренона, 0,1 - 0,2 мг ципротеронацетата, 0,2 - 0,3 мг норгестимата и 0,50 - 0,75 мг норэтистерона;
б) 5 или 4 пилюли, не содержащие лекарственного средства, или другие указания, чтобы показать, что за ежедневным приемом 23-х или 24-х дозировочных единиц должны следовать 5 или 4 дня без приема пилюль или с приемом пилюль без лекарственного средства.9. Single-phase combination product for oral contraception, characterized in that it includes:
a) 23 or 24 dosage units, depending on the circumstances, containing estrogen, selected from> 2.0–6.0 mg of 17 β-estradiol and 0.020 mg of ethinyl estradiol; and progestogen selected from> 0.06 - 0.75 mg of gestodene,> 0.100 - 0.125 mg of levonorgestrel,> 0.10 - 0.15 mg of desogestrel,> 0.10 - 0.15 mg of 3-keto-desogestrel, 0 , 25 - 0.30 mg of drospirenone, 0.1 - 0.2 mg of cyproterone acetate, 0.2 - 0.3 mg of norgestimate and 0.50 - 0.75 mg of norethisterone;
b) 5 or 4 medication-free pills or other indications to show that the daily intake of 23 or 24 dosage units should be followed 5 or 4 days without taking the pills or taking the pills without medication. 10. Однофазный комбинированный препарат для пероральной контрацепции по п. 9, отличающийся тем, что эстрогеном является этинилэстрадиол. 10. Single-phase combination preparation for oral contraception under item 9, characterized in that the estrogen is ethinyl estradiol. 11. Однофазный комбинированный препарат по п. 9 или 10, отличающийся тем, что гестагеном является гестоден. 11. Single-phase combination preparation according to claim 9 or 10, characterized in that the gestogen is gestodene. 12. Однофазный комбинированный препарат по п. 9 или 10, отличающийся тем, что гестагеном является левоноргестрел. 12. Single-phase combined preparation according to claim 9 or 10, characterized in that the progestogen is levonorgestrel. 13. Однофазный комбинированный препарат по п. 9 или 10, отличающийся тем, что гестагеном является ципротеронацетат или дроспиренон. 13. Single-phase combination preparation according to claim 9 or 10, characterized in that the gestagen is cyproterone acetate or drospirenone. 14. Однофазный комбинированный препарат по п. 9, отличающийся тем, что эстроген находится в дозе 20 мкг этинилэстрадиола или в эквивалентной дозе 17 β -эстрадиола и гестаген находится в дозе 75 мкг гестодена или эквивалентной дозу левоноргестрела, ципротеронацетата или дроспиренона. 14. The single-phase combination preparation of claim 9, wherein the estrogen is in a dose of 20 μg of ethinyl estradiol or in an equivalent dose of 17 β-estradiol and the gestagen is in a dose of 75 μg of gestodene or the equivalent dose of levonorgestrel, tsiproteroneacetate or drospirenone. 15. Однофазный комбинированный препарат по любому из пп. 9 - 13, отличающийся тем, что он включает 23 дозировочных единицы и 5 пилюль без лекарственного средства, или другие указания, чтобы показать, что в течение последних 5 дней менструального цикла не вводят никакой дозировочной единицы или принимают пилюлю без лекарственного средства. 15. Single-phase combination preparation according to any one of claims. 9-13, characterized in that it includes 23 dosage units and 5 pills without a drug, or other indications to show that during the last 5 days of the menstrual cycle no dosage unit has been administered or to take a pill without a drug. 16. Однофазный комбинированный препарат по п. 9, отличающийся тем, что он включает 23 дозировочных единицы, содержащих по 20 мкг этинилэстрадиола и 75 мкг гестодена, и 5 пилюль без лекарственного средства, или другие указания, чтобы показать, что в течение последних 5 дней менструального цикла не вводят никакой дозировочной единицы или принимают пилюлю без лекарственного средства. 16. Single phase combination preparation according to claim. 9, characterized in that it includes 23 dosage units containing 20 μg of ethinyl estradiol and 75 μg of gestodene each, and 5 pills without a drug, or other indications to show that during the last 5 days the menstrual cycle does not introduce any dosage unit or take a pill without a drug.
RU96115196/14A 1993-12-22 1994-12-22 Contraception method for being used by women of reproductive period not accessing premenopausal period RU2169567C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4344462A DE4344462C2 (en) 1993-12-22 1993-12-22 Composition for contraception
DEP4344462.8 1993-12-22

Publications (2)

Publication Number Publication Date
RU96115196A true RU96115196A (en) 1998-10-27
RU2169567C2 RU2169567C2 (en) 2001-06-27

Family

ID=6506206

Family Applications (1)

Application Number Title Priority Date Filing Date
RU96115196/14A RU2169567C2 (en) 1993-12-22 1994-12-22 Contraception method for being used by women of reproductive period not accessing premenopausal period

Country Status (21)

Country Link
US (7) US5583129A (en)
EP (2) EP1726308A3 (en)
JP (4) JPH09506888A (en)
KR (1) KR100369206B1 (en)
CN (2) CN100377713C (en)
AT (1) ATE344038T1 (en)
CA (1) CA2179728C (en)
CZ (1) CZ296387B6 (en)
DE (2) DE4344462C2 (en)
DK (1) DK0735883T3 (en)
ES (1) ES2276391T3 (en)
HK (1) HK1077743A1 (en)
HU (1) HUT74877A (en)
NL (1) NL300329I1 (en)
NO (1) NO316257B1 (en)
NZ (1) NZ278058A (en)
PL (1) PL187818B1 (en)
PT (1) PT735883E (en)
RU (1) RU2169567C2 (en)
SK (1) SK285965B6 (en)
WO (1) WO1995017194A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2449796C2 (en) * 1999-08-31 2006-02-10 Байер Шеринг Фарма Акциенгезельшафт Pharmaceutical combination of ethinylestradiol and drospirenone uses as contraceptive

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4344462C2 (en) 1993-12-22 1996-02-01 Schering Ag Composition for contraception
US6309843B1 (en) 1994-10-25 2001-10-30 The Curators Of The University Of Missouri Glycoprotein for use in determining endometrial receptivity
CA2205897A1 (en) * 1994-11-22 1996-05-30 Malcolm Cecil Pike Compositions and methods for contraception and for treatment of benign gynecological disorders
DE19513662A1 (en) * 1995-04-08 1996-10-10 Schering Ag Combined pharmaceutical preparation for hormonal contraception
DE19540253C2 (en) * 1995-10-28 1998-06-04 Jenapharm Gmbh Multi-phase preparation for contraception based on natural estrogens
AU2746097A (en) * 1996-05-08 1997-11-26 American Home Products Corporation Oral contraceptive
US5747480A (en) * 1996-05-08 1998-05-05 American Home Products Corporation Oral contraceptive
US6451778B1 (en) 1996-07-26 2002-09-17 Wyeth Oral contraceptive
WO1998004267A1 (en) * 1996-07-26 1998-02-05 American Home Products Corporation Progestin/estrogen oral contraceptive
US6479475B1 (en) 1996-07-26 2002-11-12 Wyeth Oral contraceptive
ATE271386T1 (en) * 1996-07-26 2004-08-15 Wyeth Corp ORAL SINGLE STAGE CONTRACEPTION METHOD AND COMBINATION PRODUCT CONTAINING PROGESTEN AND ESTROGEN
JP2000515889A (en) * 1996-07-26 2000-11-28 アメリカン・ホーム・プロダクツ・コーポレイション Biphasic contraceptive method and kit comprising a mixture of progestin and estrogen
US5858405A (en) * 1996-07-26 1999-01-12 American Home Products Corporation Oral contraceptive
IL127923A (en) * 1996-07-26 2004-07-25 Wyeth Corp Oral contraceptive
US5888543A (en) * 1996-07-26 1999-03-30 American Home Products Corporation Oral contraceptives
US6028064A (en) * 1996-09-13 2000-02-22 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of progestin products
FR2754179B1 (en) * 1996-10-08 1998-12-24 Theramex NOVEL HORMONONAL COMPOSITION AND ITS USE
WO2001030355A1 (en) 1999-10-25 2001-05-03 Laboratoire Theramex Contraceptive medicine based on a progestational agent and an oestrogen and preparation method
US6987101B1 (en) * 1996-12-20 2006-01-17 Schering Aktiengesellschaft Therapeutic gestagens for the treatment of premenstrual dysphoric disorder
DE19654609A1 (en) * 1996-12-20 1998-06-25 Schering Ag Therapeutic progestogens for the treatment of premenstrual dysphoric disorder
US5898032A (en) 1997-06-23 1999-04-27 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
JP4354667B2 (en) * 1999-08-31 2009-10-28 バイエル・シエーリング・ファーマ・アクチエンゲゼルシャフト Medicinal combination of ethinylestradiol and drospirenone for use as a contraceptive
US6787531B1 (en) * 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
US20020132801A1 (en) * 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
US7025979B2 (en) * 2000-02-15 2006-04-11 Schering Ag Male contraceptive formulation comprising norethisterone
US20040176336A1 (en) * 2000-03-21 2004-09-09 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US20050113351A1 (en) * 2000-03-21 2005-05-26 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
DE10045380A1 (en) 2000-09-14 2002-04-04 Schering Ag Contraception procedure and dosage form
EP1216712A1 (en) * 2000-12-20 2002-06-26 Schering Aktiengesellschaft Cyclodextrin-drospirenone inclusion complexes
US20060142257A1 (en) * 2001-01-19 2006-06-29 Eberhard Nieschlag Male contraceptive formulation comprising norethisterone
EP1406634A1 (en) * 2001-07-13 2004-04-14 Schering Aktiengesellschaft Combination of drospirenone and an estrogen sulphamate for hrt
EP1453521B1 (en) 2001-12-05 2013-09-04 Teva Women's Health, Inc. Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
US6962908B2 (en) * 2001-12-21 2005-11-08 Warner Chilcott Company Inc. Oral pharmaceutical products containing 17 β-estradiol-3-lower alkanoate, method of administering the same and process of preparation
CA2483554A1 (en) * 2002-04-26 2003-11-06 Schering Aktiengesellschaft Treatment of hypertension in women receiving hormone replacement therapy
US7786101B2 (en) * 2002-11-05 2010-08-31 Bayer Schering Pharma Ag Cardiovascular protection using anti-aldosteronic progestins
GB0302572D0 (en) 2003-02-05 2003-03-12 Astrazeneca Ab Method of treatment
US7772219B2 (en) * 2003-05-02 2010-08-10 Teva Women's Health, Inc. Methods of hormonal treatment utilizing extended cycle contraceptive regimens
AU2004257772B2 (en) * 2003-07-16 2009-12-17 Teva Women's Health, Inc. Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration
DE102004019743B4 (en) 2004-04-20 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Multiphase preparation for contraception based on natural estrogen
MY151322A (en) * 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
DE102004026670A1 (en) 2004-05-28 2005-12-15 Grünenthal GmbH Hormonal contraceptive containing a combination of ethinylestradiol and chlormadinone acetate
US8501720B2 (en) * 2004-07-30 2013-08-06 Bayer Pharma AG Method for treatment of dysmenorrhea
US20070111975A1 (en) 2004-10-07 2007-05-17 Duramed Pharmaceuticals, Inc. Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens
JP2008538748A (en) * 2005-04-07 2008-11-06 ハイシアム， インコーポレイテッド Improved methods and compositions for the prevention of anxiety, substance abuse and dependence
TW200727920A (en) * 2005-06-21 2007-08-01 Organon Nv New regimens for oral monophasic contraceptives
TW200744610A (en) * 2005-06-21 2007-12-16 Organon Nv New regimens for controlled drug delivery devices for contraception
US8153616B2 (en) * 2005-10-17 2012-04-10 Bayer Pharma Aktiengesellschaft Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same
EP1930010A1 (en) * 2006-10-20 2008-06-11 Bayer Schering Pharma Aktiengesellschaft Application of estradiol valerate or 17ß-estradiol in combination with dienogest for oral therapy to maintain and/or increase the female libido
US20080242650A1 (en) * 2007-03-26 2008-10-02 Jean-Louis Thomas Oral contraceptive regimen
DE102007027636A1 (en) * 2007-06-12 2008-12-18 Bayer Schering Pharma Aktiengesellschaft 17β-Cyano-18α-homo-19-nor-androst-4-ene derivative, its use and the derivative-containing drug
DE102007027637A1 (en) * 2007-06-12 2008-12-18 Bayer Schering Pharma Aktiengesellschaft 17β-cyano-19-nor-androst-4-ene derivative, its use and the derivative-containing drug
ES2715985T3 (en) 2007-09-06 2019-06-07 Coca Cola Co Systems and methods for monitoring and controlling the dispensing of a plurality of ingredients that constitute a beverage
RU2496711C2 (en) 2007-09-06 2013-10-27 Дзе Кока-Кола Компани System and method for programming versions of drink dispensing in appropriate drin dispenser
CA2740005C (en) 2008-10-08 2016-11-01 Agile Therapeutics, Inc. Transdermal delivery
CA2740004A1 (en) 2008-10-08 2010-04-15 Agile Therapeutics, Inc. Transdermal delivery
US9198876B2 (en) 2008-10-08 2015-12-01 Agile Therapeutics, Inc. Contraceptive transdermal delivery of hormones
EP2410859A4 (en) 2009-03-27 2013-03-13 Agile Therapeutics Inc Transdermal delivery
US9619958B2 (en) 2012-06-12 2017-04-11 Elwha Llc Substrate structure duct treatment system and method for ingestible product system and method
US20130054255A1 (en) * 2011-08-26 2013-02-28 Elwha LLC, a limited liability company of the State of Delaware Controlled substance authorization and method for ingestible product preparation system and method
US20130331981A1 (en) 2012-06-12 2013-12-12 Elwha LLC, a limited liability company of the State of Delaware Substrate Structure Deposition Treatment System And Method For Ingestible Product System And Method
US8989895B2 (en) 2011-08-26 2015-03-24 Elwha, Llc Substance control system and method for dispensing systems
US9240028B2 (en) 2011-08-26 2016-01-19 Elwha Llc Reporting system and method for ingestible product preparation system and method
US10026336B2 (en) 2011-08-26 2018-07-17 Elwha Llc Refuse intelligence acquisition system and method for ingestible product preparation system and method
US9922576B2 (en) 2011-08-26 2018-03-20 Elwha Llc Ingestion intelligence acquisition system and method for ingestible material preparation system and method
US9997006B2 (en) 2011-08-26 2018-06-12 Elwha Llc Treatment system and method for ingestible product dispensing system and method
US9111256B2 (en) 2011-08-26 2015-08-18 Elwha Llc Selection information system and method for ingestible product preparation system and method
US9037478B2 (en) 2011-08-26 2015-05-19 Elwha Llc Substance allocation system and method for ingestible product preparation system and method
US10192037B2 (en) 2011-08-26 2019-01-29 Elwah LLC Reporting system and method for ingestible product preparation system and method
US9947167B2 (en) 2011-08-26 2018-04-17 Elwha Llc Treatment system and method for ingestible product dispensing system and method
US9785985B2 (en) 2011-08-26 2017-10-10 Elwha Llc Selection information system and method for ingestible product preparation system and method
US8892249B2 (en) 2011-08-26 2014-11-18 Elwha Llc Substance control system and method for dispensing systems
US10121218B2 (en) 2012-06-12 2018-11-06 Elwha Llc Substrate structure injection treatment system and method for ingestible product system and method
US20140122120A1 (en) * 2012-10-30 2014-05-01 Pacesetter, Inc. Systems and methods for providing photo-based patient verification for use with implantable medical device programmers
CN104546870B (en) * 2015-01-27 2018-01-12 唐凡兰 A kind of contraceptive
RU2664437C2 (en) * 2016-09-29 2018-08-17 Общество с ограниченной ответственностью "Научно-производственная компания "СКиФФ" Means of prolonged action on the basis of proligestone to suppress estrus in small animals
CN110548034A (en) * 2019-07-12 2019-12-10 广州莎蔓生物科技有限公司 Pregnancy-blocking medicine
US11376263B2 (en) 2020-10-08 2022-07-05 Fortress Biotech, Inc. Cyproterone acetate compositions and uses thereof

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3639600A (en) 1969-08-28 1972-02-01 Upjohn Co Process of establishing cyclicity in a human female
DE2310963A1 (en) 1972-04-14 1974-09-05 Schering Ag METHOD OF CONTRACTION BY FOLLOWING STAGE COMBINATION PREPARATIONS
US3969502A (en) 1972-04-14 1976-07-13 Schering Aktiengesellschaft Method for contraception by the administration of sequential contraceptive preparations
US3932635A (en) 1972-04-24 1976-01-13 Syntex Corporation Novel cyclic progestogen-interrupted estrogen oral contraceptive regimens
US3927046A (en) 1972-12-09 1975-12-16 Akzona Inc Novel 11,11-alkylidene steroids
DE2546062A1 (en) 1975-10-10 1977-04-21 Schering Ag (17)-Alkynyl-(17)-hydroxy-(4,15)-oestradienones and derivs. - progestational agents inhibiting ovulation and implantation
US4145416A (en) 1976-06-23 1979-03-20 Schering, A.G. Novel agents and novel methods for treatment of climacteric disturbances
DE2652761C2 (en) 1976-11-16 1985-11-21 Schering AG, 1000 Berlin und 4709 Bergkamen 15,16-methylene-spirolactones, processes for their preparation and pharmaceuticals containing them
DE3022337A1 (en) 1980-06-11 1982-01-07 Schering Ag Berlin Und Bergkamen, 1000 Berlin Compsns. for contraception or treatment of gynaecological disorders - contg. 6 beta, 7 beta; 15 delta, 16 beta-di:methylene-3-oxo-4-androstene-17(beta-1')-spiro-5'-per:hyd- ro-furan-2'-one
DE3023233C2 (en) 1980-06-21 1982-04-08 Berg & Co Gmbh, 4800 Bielefeld Pressure medium distributor for rotating clamping cylinders with clamping pistons that can be axially displaced therein on machine tools, in particular multi-spindle lathes
US4826831A (en) 1983-08-05 1989-05-02 Pre Jay Holdings Limited Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens
AU582540B2 (en) * 1983-08-05 1989-04-06 Pre Jay Holdings Ltd. A method of hormonal treatment of perimenopausal, menopausal and post-menopausal disorders and multi-preparation pack therefor
US4616006A (en) * 1983-09-26 1986-10-07 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
DE3414508A1 (en) 1984-04-13 1985-10-24 Schering AG, 1000 Berlin und 4709 Bergkamen MULTIPLE TRITLED STEROID-20.17-SPIROLACTONE AND THEIR USE AS TRACER SUBSTANCES
US5010070A (en) 1987-06-15 1991-04-23 Warner-Lambert Company Graduated estrogen contraceptive
US5208225A (en) 1986-02-27 1993-05-04 Warner-Lambert Company Compositions containing fixed combinations
IE61236B1 (en) * 1986-07-15 1994-10-19 American Home Prod Combination dosage form for pre-menopausal women
US5256421A (en) 1987-09-24 1993-10-26 Jencap Research Ltd. Hormone preparation and method
US5108995A (en) 1987-09-24 1992-04-28 Jencap Research Ltd. Hormone preparation and method
DK174071B1 (en) * 1987-09-24 2002-05-21 Jencap Res Ltd Contraceptive preparation in the form of a package comprising unit doses
US5422119A (en) 1987-09-24 1995-06-06 Jencap Research Ltd. Transdermal hormone replacement therapy
DE3916112A1 (en) 1989-05-16 1990-11-22 Schering Ag DIHYDROSPIRORENONE AS AN ANTIANDROGEN
US5098714A (en) 1989-11-16 1992-03-24 Alza Corporation Osmotic, oral dosage form for fertility control
IE71203B1 (en) * 1990-12-13 1997-02-12 Akzo Nv Low estrogen oral contraceptives
IE62665B1 (en) 1990-12-17 1995-02-22 Akzo Nv Contraceptive regimen
US5211952A (en) 1991-04-12 1993-05-18 University Of Southern California Contraceptive methods and formulations for use therein
EP0640343A1 (en) 1993-07-01 1995-03-01 Leiras Oy Contraceptive for oral use containing oestradial valerate and cyproterone acetate
DE4344462C2 (en) 1993-12-22 1996-02-01 Schering Ag Composition for contraception
DE4411585A1 (en) 1994-03-30 1995-10-05 Schering Ag Combined pharmaceutical preparation for hormonal contraception
US5552394A (en) * 1994-07-22 1996-09-03 The Medical College Of Hampton Roads Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy
DE19510862A1 (en) 1995-03-16 1996-09-19 Schering Ag Use of antiestrogens for male fertility control
WO1998004246A2 (en) 1996-07-26 1998-02-05 American Home Prod Triphasic contraceptive method and kit comprising a combination of a progestin and estrogen
ATE271386T1 (en) 1996-07-26 2004-08-15 Wyeth Corp ORAL SINGLE STAGE CONTRACEPTION METHOD AND COMBINATION PRODUCT CONTAINING PROGESTEN AND ESTROGEN
JP2000515889A (en) 1996-07-26 2000-11-28 アメリカン・ホーム・プロダクツ・コーポレイション Biphasic contraceptive method and kit comprising a mixture of progestin and estrogen
WO1998004267A1 (en) 1996-07-26 1998-02-05 American Home Products Corporation Progestin/estrogen oral contraceptive
IL127923A (en) 1996-07-26 2004-07-25 Wyeth Corp Oral contraceptive
FR2754179B1 (en) 1996-10-08 1998-12-24 Theramex NOVEL HORMONONAL COMPOSITION AND ITS USE
ES2314156T3 (en) 2003-03-28 2009-03-16 Pantarhei Bioscience B.V. ANTI-CONTRACEPTIVE METHOD FOR FEMALE AND KIT MAMMERS TO USE IN THIS METHOD.

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2449796C2 (en) * 1999-08-31 2006-02-10 Байер Шеринг Фарма Акциенгезельшафт Pharmaceutical combination of ethinylestradiol and drospirenone uses as contraceptive
RU2269342C2 (en) * 1999-08-31 2006-02-10 Шеринг Акциенгезелльшафт Pharmaceutical combination of ethynylestradiol and drospirenone for using as contraceptive
RU2269342C9 (en) * 1999-08-31 2007-10-27 Шеринг Акциенгезелльшафт Pharmaceutical combination of ethynylestradiol and drospirenone for using as contraceptive
RU2482853C2 (en) * 1999-08-31 2013-05-27 Байер Фарма Акциенгезельшафт Pharmaceutical composition, method for preparing it and multiphase pharmaceutical preparation for ovulation inhibition in mammal

Similar Documents

Publication Publication Date Title
RU96115196A (en) COMPOSITION FOR CONTRACEPTION
JP2848919B2 (en) Medication for the treatment of premenopausal hormonal abnormalities, for menopausal hormone replacement therapy, for the treatment of androgen-induced disorders and for contraception
US9132137B2 (en) Graduated estrogen contraceptive
US5262408A (en) Low estrogen oral contraceptives
KR100186780B1 (en) Contraceptive regimen
EP1898953B1 (en) Quadraphasic continuous graduated estrogen contraceptive
RU96119957A (en) PHARMACEUTICAL COMBINED DRUG FOR HORMONAL CONTRACEPTION
CA2179728A1 (en) Composition for a contraceptive comprising an estrogen and a gestagen
ES2033850T3 (en) PHARMACEUTICAL FORM CONSISTING OF A DOSAGE COMBINATION, INTENDED FOR THE TREATMENT OF PRE-MENOPAUSIC WOMEN.
JP2000502108A (en) Contraceptive methods and kits for mammals using gestogens and estrogens
WO2006115871A1 (en) Extended estrogen dosing contraceptive regimen
US7935691B2 (en) Extended cycle multiphasic oral contraceptive kit
RU97118464A (en) PHARMACEUTICAL COMBINED DRUG FOR HORMONAL CONTRACEPTION
WO1994004156A1 (en) Antiprogestogen containing contraceptives
AU2011226911B2 (en) Management of breakthrough bleeding in extended hormonal contraceptive regimens